LON:VAL ValiRx (VAL) Share Price, News & Analysis GBX 0.14 -0.02 (-10.00%) As of 12:28 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsNews and Trends About ValiRx Stock (LON:VAL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ValiRx alerts:Sign Up Key Stats Today's Range 0.14▼ 0.1650-Day Range 0.12▼ 0.1952-Week Range 0.12▼ 0.48Volume14.03 million shsAverage Volume13.26 million shsMarket Capitalization£1.78 millionP/E RatioN/ADividend Yield0.63%Price TargetN/AConsensus RatingN/A Company Overview ValiRx accelerates the development of treatments in cancer and women’s health to improve patient lives. We provide the scientific, financial and commercial framework to enable the rapid translation of innovative science into clinical development. Read More Receive VAL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ValiRx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VAL Stock News HeadlinesUpdate on Ambrose Healthcare shareholdingOctober 21, 2026 | markets.ft.comValiRx sees value boost from Ambrose’s AM-Pharma acquisitionOctober 21, 2026 | tipranks.comMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.November 16 at 1:00 AM | Weiss Ratings (Ad)ValiRx Cuts Interim Loss as Cash Rises to £970,564 Following FundraisingSeptember 15, 2026 | uk.finance.yahoo.comValiRx tightens operations and bolsters cash as it refocuses pipeline and portfolioSeptember 15, 2026 | tipranks.comValiRx strengthens Cytolytix cancer IP with European patent progress and new filingAugust 10, 2026 | uk.finance.yahoo.comValiRx set to land second European patent for Cytolytix cancer peptideAugust 10, 2026 | uk.finance.yahoo.comValiRx subsidiary Cytolytix nears "significant" European patent winAugust 10, 2026 | lse.co.ukSee More Headlines VAL Stock Analysis - Frequently Asked Questions How have VAL shares performed this year? ValiRx's stock was trading at GBX 0.32 at the beginning of 2026. Since then, VAL shares have decreased by 58.2% and is now trading at GBX 0.14. How were ValiRx's earnings last quarter? ValiRx plc (LON:VAL) released its earnings results on Tuesday, September, 15th. The company reported GBX (0.09) earnings per share (EPS) for the quarter. ValiRx had a negative trailing twelve-month return on equity of 71.49% and a negative net margin of 6,548.06%. How do I buy shares of ValiRx? Shares of VAL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of ValiRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that ValiRx investors own include hVIVO (HVO), Lloyds Banking Group (LLOY), Sareum (SAR), Scirocco Energy Plc (SOLO.L) (SOLO), boohoo group (BOO), Chaarat Gold (CGH) and Centrica (CNA). Company Calendar Last Earnings9/15/2026Today11/16/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorEnergy Industry Oil, Gas & Consumable Fuels Sub-IndustryOil & Gas Exploration & Production Current SymbolLON:VAL CIKN/A Webwww.valirx.com Phone+44-20-30084416FaxN/AEmployees5,450Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£5.71 million Net Margins-6,548.06% Pretax MarginN/A Return on Equity-71.49% Return on Assets-35.98% Debt Debt-to-Equity RatioN/A Current Ratio10.98 Quick Ratio1.27 Sales & Book Value Annual Sales£32.67 thousand Price / Sales54.55 Cash FlowGBX 0 per share Price / Cash Flow62.50 Book ValueGBX 2.67 per share Price / Book0.05Miscellaneous Outstanding Shares1,320,301,000Free FloatN/AMarket Cap£1.78 million OptionableNot Optionable Beta0.59 Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (LON:VAL) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredIntel Shares Jumped 177% After Elon Musk's DealElon Musk's April 2026 partnership with Intel sent shares climbing 177% within two months. Jeff Brown, the ...Brownstone Research | SponsoredSmall-Cap SMX is Taking its Technology into Multiple Trillion-Dollar Industries!SMX (NASDAQ: SMX) uses proprietary molecular-marking technology and a Digital Material Passport platform to gi...Smallcaps Daily | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ValiRx plc Please log in to your account or sign up in order to add this asset to your watchlist. Share ValiRx With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.